Sustained imatinib treatment in chronic myeloid leukaemia patients can result in complete molecular response allowing discontinuation without relapse. We set out to evaluate the frequency of complete molecular response in imatinib de novo chronic-phase chronic myeloid leukaemia patients, identify baseline and under-treatment predictive factors of complete molecular response in patients achieving complete cytogenetic response and assess if complete molecular response is associated with a better outcome. Unselected patients on frontline imatinib therapy (n=266) were considered for inclusion. Complete molecular response was confirmed and defined as MR 4.5 with undetectable BCR-ABL transcript levels.
Introduction
Frontline therapy with imatinib (IM) has dramatically improved the outcome of chronic phase chronic myeloid leukaemia (CP-CML) patients. A single institution study recently reported that the 8-year survival for CML patients was ≤ 15% before 1983, 42-65% from 1983 to 2000, and 87% since 2001 (1). Estimates of long-term survival show that life expectancy is increasing to levels close to those observed in the general population (2).
The best outcome is associated with a complete hematologic response (CHR) during the first three months of treatment and a complete cytogenetic response (CCyR) during the first year of treatment (3) (4) (5) (6) . Monitoring the BCR-ABL transcript level from peripheral blood is therefore essential to evaluate the response: analysis of the molecular follow-up of the phase III International Randomized Study of Interferon vs. STI571 (IRIS) study suggests that patients achieving a CCyR with a 3-log reduction in BCR-ABL transcript level -defined as a major molecular response (MMR) -have better progression-free survival (PFS), event-free survival (EFS) compared to the other patients (7, 8) . Nevertheless, while the prognostic value of achieving MMR is well established it remains difficult to assess particularly in patients who have achieved a previous CCyR. Furthermore, not all studies correlate MMR with better EFS, PFS, and overall survival (OS) (3-5, 7, 9-11) .
Whether or not patients achieve MMR, most have persistent detectable disease at a molecular level and will have to continue IM indefinitely. However, a few patients achieve a so-called complete molecular response (CMR) which is usually defined by a minimum of a 4.5 log reduction in BCR-ABL transcript levels from the baseline value.
As well as the fact that there is an ongoing discussion about the definition of CMR, the clinical impact of achieving such a level of residual disease is unknown. Nevertheless, it has been reported that sustained CMR for more than 2 consecutive years can lead to cessation of IM treatment without molecular relapse in almost 40% of cases (12).
We set out to assess the frequency of CMR in CP-CML patients treated with IM as frontline therapy, identify both baseline and under-treatment predictive factors of CMR in patients who achieved CCyR on IM therapy, and determine whether achieving a CMR was associated with a better outcome.
Methods
Patients with diagnosed Philadelphia chromosome-positive (Ph-positive)CML referred to the two participating centers (University Hospitals of Bordeaux and Lyon) from January 2000 to March 2010 who were in chronic phase at diagnosis, treated with frontline IM were considered for inclusion in this study.
All patients provided informed consent to participate in the study. Cytogenetic responses were evaluated at least every 6 months during the first year of therapy and then every 3 to 6 months until CCyR. During follow-up and after a first CCyR documented on cytogenetic analysis, a BCR-ABL transcript level < 1% (IS) was considered as equivalent to CCyR.
Molecular response was assessed according to previously reported recommendations (13).
MMR was defined as a reduction of BCR-ABL/ABL level of at least 3 logs from a standardized baseline value and confirmed on two consecutive analyses at least two months apart. In the current work, CMR was defined as MR 4.5 with undetectable BCR-ABL transcript on two consecutive analyses at least two months apart. Loss of MMR and CMR were defined as BCR-ABL/ABL transcripts ≥ 0.1% and detectable BCR-ABL transcript respectively, both on two consecutive analyses at least two months apart.
Univariate and multivariate analyses were performed with Cox regressions. Fine and Gray models were used to analyze the cumulative incidence of molecular responses.
EFS, failure-free survival (FFS) and OS were measured from the date of the first CCyR on therapy to the date of event or death. Survival differences, estimated by Kaplan-Meier analysis for patients of the different groups, were assessed using a log-rank test.
Times to event were measured as the time between date of CCyR and the event of interest.
For censored cases, it corresponded to time between date of CCyR and the last observational period under IM. EFS referred to survival without loss of complete hematologic response, loss of CCyR, detection of a BCR-ABL domain kinase point mutation associated with a high level of IM resistance, progression to accelerated or blastic phase, death from any cause on or off therapy, treatment cessation for toxicity. FFS referred to survival without events previously described with the exception of treatment cessation for toxicity according to the ELN recommendations (14). Only the first event for an individual patient was considered.
Patients who achieved a CCyR without CMR on IM therapy with a follow-up shorter than the observed median time to CMR and without any reported event during follow-up were excluded for the identification of CMR predictive factors and survival studies.
The clinical outcomes were analysed at landmark time points. For those analyses, patients had to be still on IM and have available data regarding the molecular response status at specified time points.
The significant level of the statistical tests was set at 5%. All analyses were performed by SPSS statistical package (Chicago, IL), version 20.0.0, and R program, version 2.14.2.
Results

Patients:
Two hundred sixty-six adult patients diagnosed with Ph-positive CML-CP were treated by IM as frontline therapy during the study period in the two centers. Baseline characteristics of the population are presented in Table 1 . The median follow-up was 4.43 years (range, 0.79 to 10.8 years). Seventeen patients died, 13 from CML progression and four from unrelated (n=2) or undetermined (n=2) causes. Initial IM daily dose was 400 mg in 85% of the patients.
At the time of analysis 178 (67%) patients were still on IM.
Thirty three patients did not achieve CCyR on IM. Among them, 23 were considered to be in treatment failure according to the 2009 ELN criteria (15) (lack of complete hematologic response at 3 months, n=4; lack of cytogenetic response at 6 months, n=7; lack of CCyR at 18 months, n=10; progression to accelerated phase (AP) or blast phase (BP), n=2), and 10 had experienced a recurrent grade 3-4 toxicity leading to IM discontinuation. Among the under-treatment characteristics, predictive factors identified by univariate analysis were time from IM initiation to first CCyR, and to first MMR.
As there was an association between platelet and WBC counts, i.e. patients with a platelet count lower than 600 G/L had a higher WBC, only platelet count was entered into the final Figure 3A ]. Interestingly, achieving CCyR and MMR in the first year of therapy was associated with a higher rate of further CMR when compared to patients who had achieved CCyR without MMR at 12 months and CCyR after 12 months (p<.0001) [ Figure   3B ]. The impact of achieving MMR at 18 months was also correlated with a higher rate of further CMR as illustrated in Figure 3C (p<.0001).
Outcome:
Thirty-five (19.4%) of the 180 patients who achieved CCyR on IM therapy presented an event as previously defined [ Table 2 ].
Fifty-seven percent of the patients in CCyR without MMR, 22% of the patients with CCyR and MMR without CMR and 3% of the patients with CCyR and CMR presented an event.
The event was death for two patients: one in CCyR and MMR died of an unknown cause while the other death was related to a concomitant aggressive non-Hodgkin's lymphoma. Survival analyses were also performed including the excluded patients, i.e. patients who had a follow-up below the median observed time to CMR without event: EFS and FFS associated with CMR were still significantly better than CCyR with or without MMR (data not shown).
In order to also assess whether achieving CMR at specific time points had a clinical impact, EFS was analysed by landmark analysis according to the molecular response status at 18 months from IM start. Among the 233 patients who had achieved a CCyR on IM treatment, 20 patients had a follow-up below 18 months and 21 patients had achieved CCyR later than 18 months and were not considered from subsequent analysis. Finally among the 192 remaining patients, 19 (10%) patients were in CMR, 101 (53%) patients were in MMR and 72 (37%) patients were only in CCyR. There was no statistically significant difference in EFS between the 3 groups using landmark analysis at 18 months [ Figure 5 ], (p=.11). Among the 101 MMR patients, 42 achieved the CMR after 18 months. However no significant differences were observed at the 24 and 30 months landmark analysis. FFS and OS were also analysed by landmark at these time points but did not demonstrated statistically differences between the 3 groups of patients (data not shown).
Discussion
IM has dramatically improved outcome for newly diagnosed CML-CP patients with most achieving a sustained CCyR and MMR which are considered to be the best surrogate markers of survival. In the current study, the cumulative incidence of CCyR and MMR (respectively 88 and 74%) are similar to that reported by other studies (3-5, 11). By 2 and 3 years, 9 and 14% of the patients achieved a CMR that is also very similar to that reported by other randomized studies in IM arm (16-18). Finally, 65 (24%) patients of the study cohort achieved CMR.
The second objective of the study was to identify baseline and under-treatment prognostic factors of achieving CMR at the time of the first CCyR on IM frontline therapy: the absence of spleen enlargement, achieving CCyR during the first 12 months of therapy and achieving MMR within the year following CCyR were associated with a significantly increased probability of achieving a further CMR.
The negative prognostic value of spleen enlargement is however not very surprising. Spleen enlargement was already a strong predictive factor of survival as assessed by the Sokal and
Hasford scores before the IM era and found to predict a lower probability of achieving a Our study focused on patients who achieved CCyR on IM therapy. To date, while most patients treated with IM frontline achieve CCyR, most of these will have persistent disease at the molecular level. In the subset of patients who achieved a previous CCyR the prognostic value of MMR -defined as a 3-log reduction in BCR-ABL baseline transcript level -remains debatable (3, 5, 8, 11) . One of the reasons may be that CCyR and MMR thresholds are in close proximity for measuring residual disease: CCyR corresponds to a 2-log reduction of BCR-ABL transcript level from a baseline value and the standard deviation of quantitative BCR-ABL PCR can be around 0.5 log. Therefore, assessing the clinical impact of MMR in
CCyR patients would require a long follow up and a large cohort of patients. However, MMR has been shown to be a strong reproducible surrogate marker which is useful to compare findings from different studies.
Significantly higher rates of CMR were observed in patients who had achieved CCyR and MMR at 12 months when compared to patients who had achieved CCyR at twelve months or later without MMR. Therefore, beyond its prognostic value, a faster MMR in CCyR patients has predictive impact on the probability of achieving a further CMR. (24). We also considered that loss of a previous CCyR rather than loss of a major cytogenetic response at any time during treatment as a significant event leading to therapeutic change as recommended by the ELN experts in case of failure (15).
As molecular status for an individual patient may evolve during IM therapy, Kaplan-Meier analysis may be debatable. However, the objective of the study was to assess whether achieving a deeper molecular response in CCyR patients at any time, rather than at defined milestones, was associated with a better outcome. Indeed among patients who failed to achieve CMR, patients with a shorter follow-up than the observed median time to CMR and without any reported event were excluded from the identification of predictive factors of CMR and survival analyses. Moreover, the three groups of patients defined by the best response achieved under IM therapy have now reached a long follow-up (4.55 years for the CCyR+MMR-, 5.37 years for the CCyR+MMR+CMR-and 6.16 years for the CCyR+MMR+CMR+).
In order to compare time-to-event outcome between groups determined during study followup, landmark method have been used by other studies (8). However, the omission of events occurring earlier to the landmark time point or after is sometime the limits of the method.
Anyway, we attempted to assess whether achieving a CMR at specific time points had a clinical impact with this method. So EFS was analysed by landmark analysis according to the molecular response status at 18 months from IM start. Although a trend was observed, this 18 months landmark analysis did not demonstrate significant difference in EFS according to the depth of molecular response. Clearly, for a time dependent variable landmark analysis is an appropriate test to determine the prognostic value of the response but its does not take into account what is happening after the time point. In the current study the rate of CMR continue to increase after 18 months. In contrast, using Kaplan-Meier method the best molecular response achieved was taken into account independently to the time. So, the Kaplan-Meier analyses show that the achievement of CMR during the follow up is associated with a lower probability of clinically relevant events.
Until now the relevance of deeper molecular response was mainly linked to the strategies of IM discontinuation. The STIM study demonstrated that achievement of sustained CMR (for at least 2 years) was one of first but essential criteria when considering IM discontinuation (12).
However, besides discontinuation strategies, the impact of achieving CMR on clinical outcome and survival has not previously been demonstrated. Colombat et al. showed that failure to achieve a sustained CMR for patients in CCyR was correlated to the probability of loss of CCyR (25) In the current study we demonstrated that once CCyR is achieved with frontline IM achieving a deeper molecular response is associated with a lower probability of relevant clinical events.
Conclusion
probability of remaining in CMR at two years. The absences of spleen enlargement, absence of achievement of a CCyR before 12 months and MMR in the first year following CCyR achievement, were predictive of achieving a further CMR. Our study demonstrates that once CCyR has been reached, achieving deeper molecular response is associated with a better EFS and FFS and that CMR clearly confers the best outcome and should thus become the main objective of CML therapies.
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